Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI guides Doctors' lungs scope in pneumonia battle

NCT ID NCT07230431

Diagnosis Sponsor: Chinese Medical Association Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests an AI system that helps doctors navigate a bronchoscope (a thin tube with a camera) into the lungs of patients with severe pneumonia. The AI provides real-time visual cues and voice prompts to guide the doctor to the right spot and describe what they see. About 100 adults will take part across multiple hospitals in China. The goal is to see if AI assistance improves diagnostic accuracy and reduces procedure time compared to standard bronchoscopy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Embodied-Intelligence-Assisted Bronchoscopy Navigation and Diagnostic System (EIBRONCH) - an AI software/hardware device that provides real-time visual and voice guidance during bronchoscopy
What this could lead to
If successful, this AI system could help doctors perform bronchoscopy more accurately and quickly, potentially improving diagnosis and treatment for severe pneumonia patients.
What could go wrong
This is an early-stage study with only 100 participants, so results may not apply to all patients. The AI is decision-support only, and technical issues or user error could limit its benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years. 2. Severe pneumonia requiring clinically indicated bronchoscopy for diagnosis and/or therapy, as determined by the treating team. 3. Written informed consent from the patient or a legally authorized representative. 4. Expected to tolerate bronchoscopy with current respiratory support (e.g., HFNC/NIV/IMV) per site protocol Exclusion Criteria: 1. Standard contraindications to bronchoscopy, such as uncontrolled hypoxemia despite support (SpO2 \<90% for ≥30 s on FiO2 ≥0.60), hemodynamic instability requiring escalating vasopressors, or malignant arrhythmia not controlled. 2. Uncorrected coagulopathy likely to increase bleeding risk (e.g., platelets \<50×10\^9/L or INR \>1.5) per site policy. 3. Known pregnancy or breastfeeding if the investigator judges risk outweighs benefit according to site policy. 4. Participation in another interventional drug/device study that could interfere with outcomes. 5. Any condition that, in the investigator's judgment, makes participation unsuitable (e.g., emergent life-saving bronchoscopy without time for consent).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumonia respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia Respiratory failure (pediatric patients)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.